Stem cell-derived retinal cells need primary cilia to support survival of light-sensing photoreceptors
Scientists at the National Eye Institute (NEI), part of the National Institutes of Health, report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE)—a layer of cells in the back of the eye—are essential for the survival of the retina’s light-sensing photoreceptors. The discovery has advanced efforts to make stem cell-derived RPE for transplantation into patients with geographic atrophy, otherwise known as dry age-related macular degeneration (AMD), a leading cause of blindness in the U.S. The study appears in the January 2 Cell Reports.
“We now have a better idea about how to generate and replace RPE cells, which appear to be among the first type of cells to stop working properly in AMD,” said the study’s lead investigator, Kapil Bharti, Ph.D., Stadtman investigator at the NEI. Bharti is leading the development of patient stem cell-derived RPE for an AMD clinical trial set to launch in 2018.
In a healthy eye, RPE cells nourish and support photoreceptors, the cells that convert light into electrical signals that travel to the brain via the optic nerve. RPE cells form a layer just behind the photoreceptors. In geographic atrophy, RPE cells die, which causes photoreceptors to degenerate, leading to vision loss.
Bharti and his colleagues are hoping to halt and reverse the progression of geographic atrophy by replacing diseased RPE with lab-made RPE. The approach involves using a patient’s blood cells to generate induced-pluripotent stem cells (iPSCs), cells capable of becoming any type of cell in the body. iPSCs are grown in the laboratory and then coaxed into becoming RPE for surgical implantation.
Attempts to create functional RPE implants, however, have hit a recurring obstacle: iPSCs programmed to become RPE cells have a tendency to get developmentally stuck, said Bharti. “The cells frequently fail to mature into functional RPE capable of supporting photoreceptors. In cases where they do mature, however, RPE maturation coincides with the emergence of primary cilia on the iPSC-RPE cells.”
The researchers tested three drugs known to modulate the growth of primary cilia on iPSC-derived RPE. As predicted, the two drugs known to enhance cilia growth significantly improved the structural and functional maturation of the iPSC-derived RPE. One important characteristic of maturity observed was that the RPE cells all oriented properly, correctly forming a single, functional monolayer. The iPSC-derived RPE cell gene expression profile also resembled that of adult RPE cells. And importantly, the cells performed a crucial function of mature RPE cells: they engulfed the tips of photoreceptor outer segments, a pruning process that keeps photoreceptors working properly.
By contrast, iPSC-derived RPE cells exposed to the third drug, an inhibitor of cilia growth, demonstrated severely disrupted structure and functionality.
As further confirmation of their observations, when the researchers genetically knocked down expression of cilia protein IFT88, the iPSC-derived RPE showed severe maturation and functional defects, as confirmed by gene expression analysis. Tissue staining showed that knocking down IFT88 led to reduced iPSC-derived RPE cell density and functional polarity, i.e., cells within the RPE tissue pointed in the wrong direction.
Bharti and his group found similar results in iPSC-derived lung cells, another type of epithelial cell with primary cilia. When iPSC-derived lung cells were exposed to drugs that enhance cilia growth, immunostaining confirmed that the cells looked structurally mature.
The report suggests that primary cilia regulate the suppression of the canonical WNT pathway, a cell signaling pathway involved in embryonic development. Suppression of the WNT pathway during RPE development instructs the cells to stop dividing and to begin differentiating into adult RPE, according to the researchers.
The researchers also generated iPSC-derived RPE from a patient with ciliopathy, a disorder that causes severe vision loss due to photoreceptor degeneration. The patient’s ciliopathy was associated with mutations of cilia gene CEP290. Compared to a healthy donor, iPSC-derived RPE from the ciliopathy patient had cilia that were smaller. The patient’s iPSC-derived RPE also had maturation and functional defects similar to those with IFT88 knockdown.
Further studies in a mouse model of ciliopathy confirmed an important temporal relationship: Looking across several early development stages, the RPE defects preceded the photoreceptor degeneration, which provides additional insights into ciliopathy-induced retinal degeneration.
The Latest on: Dry age-related macular degeneration
- Age-Related Macular Degeneration Market Is Expected to Expand at an Impressive Rate by 2025 on December 11, 2018 at 10:47 pm
The age-related macular degeneration market can be broadly categorized on the basis of type of AMD, type of drug, route of administration, and geography. Based on type of AMD, the market can be segmen... […]
- Global Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2018 - ResearchAndMarkets.com on October 26, 2018 at 8:21 am
DUBLIN--(BUSINESS WIRE)--The "Global Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Global Dry Age-Related Ma... […]
- Global Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2018 - ResearchAndMarkets.com on October 26, 2018 at 1:22 am
The "Global Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Global Dry Age-Related Macular Degeneration Market ... […]
- Optos Announces Collaboration for Monitoring and Treating Dry Age-Related Macular Degeneration in Europe on October 24, 2018 at 4:11 am
Optos Plc, a subsidiary of Nikon Corporation, Japan and the only ultra-widefield retinal imaging company for eye care is pleased to announce an exclusive distribution agreement in Europe and Australia ... […]
- “Age Related Macular Degeneration Market” on September 27, 2018 at 10:14 pm
By type, the market is segmented into wet age-related macular degeneration (Wet AMD) and dry age-related macular degeneration (Dry AMD). Wet AMD accounts for more than 50% of the total market and is e... […]
- Pixium Vision achieves successful activation of its photovoltaic PRIMA implant in all five study patients with Dry Age-related Macular Degeneration on August 29, 2018 at 10:10 pm
Pixium Vision achieves successful activation of its photovoltaic PRIMA implant in all five study patients with Dry Age-related Macular Degeneration Paris, France. August 30, 2018 - 7.00 AM CEST - Pixi... […]
- Gene Therapy for Age-related Macular Degeneration Pipeline Analysis Report 2018 Featuring RetroSense Therapeutics, REGENXBIO & AGTC on June 15, 2018 at 10:08 am
the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD ... […]
- Macular Degeneration on May 10, 2018 at 10:22 pm
There are two forms of age related macular degeneration: wet neovascular age related macular degeneration, and dry atrophy age related macular degeneration. Wet progresses rapidly over a few weeks to ... […]
- Stem cells treat macular degeneration on March 19, 2018 at 12:12 pm
Credit: University of California - Santa Barbara In July 2015, 86-year-old Douglas Waters developed severe age-related macular degeneration (AMD ... center of the retina and almost always begins as dr... […]
- Macular degeneration — Most frequently asked questions on March 1, 2018 at 10:28 pm
Yes, they are both same things, because this disease develops as the person ages its is often referred to as age related macular degeneration There are two types : wet macular degeneration and dry mac... […]
via Google News and Bing News